Previous close | 212.80 |
Open | 212.70 |
Bid | 210.90 x 0 |
Ask | 217.50 x 0 |
Day's range | 212.30 - 215.20 |
52-week range | 153.85 - 252.80 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
WILMINGTON, Mass., April 22, 2024--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.